©Reuters.
MALVERN, Pennsylvania – TELA Bio, Inc. (NASDAQ: NASDAQ:), a medical technology company, announced the U.S. launch of its FDA-cleared LIQUIFIX devices for hernia repair. LIQUIFIX FIX8™ and LIQUIFIX Precision™ are designed for laparoscopic and open femoral and inguinal hernia repair, respectively.
These devices represent the only FDA-approved options for securing mesh and approximating peritoneal tissue using liquid anchors, which could potentially reduce mechanical tissue trauma while avoiding the use of penetrating tacks, sutures, or staples. This non-penetrating approach allows for precise fixation of the mesh and minimizes the risk of complications.
LIQUIFIX products are particularly useful for fixing mesh in sensitive areas known as the “triangle of doom” and “triangle of pain”, where traditional fixation methods could lead to vascular or nerve injury and chronic pain.
With more than 1.2 million hernia surgeries performed annually in the United States, the introduction of LIQUIFIX could have a significant impact on surgical practices. Consultant general surgeon Paul Wilson, who has used the device in the UK, attested to its ease of use and effectiveness, noting a reduction in both acute post-operative pain and chronic pain.
Manufactured by UK-based Advanced Medical Solutions Limited, LIQUIFIX products have shown strong performance in Europe and other international markets over the past three years. The US launch is facilitated by TELA Bio’s agreement with AMS, leveraging TELA’s expanding sales force and focusing on new technologies.
LIQUIFIX devices are indicated for use with polypropylene or polyester prosthetic meshes and are contraindicated for patients with sensitivity to certain adhesives or dyes, as well as for PTFE meshes or for specific types of tissue fixation.
The company’s press release serves as the source for this information.
Insights on InvestingPro
As TELA Bio, Inc. (NASDAQ: TELA) makes strides in the medical technology industry with its innovative LIQUIFIX devices, the company’s financial health and market performance remain key drivers for investors. TELA holds a market capitalization of $138.85 million, reflecting its position in the industry. Despite the promising launch of its FDA-approved products, TELA’s financial metrics indicate some challenges. The company’s P/E ratio stands at -2.79, with an adjusted P/E ratio for the trailing twelve months as of Q3 2023 at -3.16, signifying that the company is currently unprofitable.
Furthermore, TELA’s revenue growth has been robust, increasing by 39.05% over the trailing twelve months as of Q3 2023, suggesting strong market demand for its products. However, a tip from InvestingPro reveals that analysts do not expect TELA to be profitable this year, which could be a point of consideration for potential investors. Furthermore, the company’s shares have seen a decline over the past month, with a 1-month total price return of -21.29%.
For those interested in learning more about TELA’s financial outlook, InvestingPro offers further insights. There are currently 5 more InvestingPro tips available, which could help investors make more informed decisions. To access these tips and take advantage of real-time metrics, visit https://www.investing.com/pro/TELA. Don’t forget to use the coupon code PRONEWS24 for an additional 10% discount on an annual or two-year Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For further information please see our T&Cs.